Above, a paper was discussed that contained references to the platform level. Now, Faron is indeed seeking a patent for recombinant fragments of Clever-1, which can be used as biomarkers in research or perhaps even as new drug candidates.
Would it be suitable for inflammatory diseases or fibrosis, for example? Bex inhibits, but perhaps Clever-1 could be modulated in different directions.
At least now, IP is being sought that expands beyond Bex to cover some utilization of the Clever-1 mechanism.